Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$817K Buy
6,355
+833
+15% +$101K 0.01% 372
2023
Q1
$621K Buy
5,522
+56
+1% +$6.27K 0.01% 381
2022
Q4
$619K Buy
5,466
+714
+15% +$78.4K 0.01% 362
2022
Q3
$383K Buy
4,752
+261
+6% +$22.1K 0.01% 367
2022
Q2
$335K Buy
4,491
+1,307
+41% +$119K 0.01% 378
2022
Q1
$407K Buy
3,184
+1,116
+54% +$122K 0.01% 371
2021
Q4
$277K Buy
2,068
+588
+40% +$84.5K 0.01% 378
2021
Q3
$236K Buy
+1,480
New +$187K ﹤0.01% 369

Other funds holding DXCM

PFS Investments's DXCM Position: Q2 2023 in Review

PFS Investments increased its DexCom (DXCM) stake by 15% in Q2 2023, buying an estimated $101K and bringing the position to 6,355 shares worth $817K. The position accounts for 0.01% of the portfolio, ranked #372.

PFS Investments first reported a position in DXCM in Q3 2021 and has held it in 8 quarters since. 954 funds tracked by Wall St. Rank hold DXCM as of Q2 2023.

  • PFS Investments held 6,355 shares of DexCom worth $817K as of Q2 2023.
  • PFS Investments bought 833 DexCom shares in Q2 2023, an estimated $101K.
  • DexCom made up 0.01% of PFS Investments's portfolio in Q2 2023, its #372 holding.
  • PFS Investments first reported a position in DexCom in Q3 2021 and has held it in 8 quarters since.
  • 954 funds tracked by Wall St. Rank held DexCom as of Q2 2023.

Based on PFS Investments's 13F filing for Q2 2023, filed 14 Aug 2023.